Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.
about
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapyCombinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitorDisparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virusSynergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytesPotentiation of the anti-HIV activity of zalcitabine and lamivudine by a CTP synthase inhibitor, 3-deazauridineComparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cellsIn vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosineIncreased activation of the combination of 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine in the presence of hydroxyureaEffects of RP 55778, a tumor necrosis factor alpha synthesis inhibitor, on antiviral activity of dideoxynucleosidesBroad-spectrum agents for flaviviral infections: dengue, Zika and beyondPhosphorylation of nucleoside analog antiretrovirals: a review for clinicians.Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivoSAMHD1 specifically affects the antiviral potency of thymidine analog HIV reverse transcriptase inhibitorsImmunomodulatory effect of zidovudine (ZDV) on cytotoxic T lymphocytes previously exposed to ZDVR5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitorsDepot-medroxyprogesterone acetate does not reduce the prophylactic efficacy of emtricitabine and tenofovir disoproxil fumarate in macaques.Pre-steady-state kinetic analysis of the incorporation of anti-HIV nucleotide analogs catalyzed by human X- and Y-family DNA polymerases.HIV-1 drug resistance: can we overcome?Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcriptionUse of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compoundsA Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNAActivity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine.Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro.A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.DNA polymerases as therapeutic targetsAnti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir.Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients.Intracellular nucleotides of (-)-2',3'-deoxy-3'-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus.Diminished human immunodeficiency virus type 1 reverse transcription and nuclear transport in primary macrophages arrested in early G(1) phase of the cell cycle
P2860
Q28367526-68E2C7AA-849A-4BA9-96BC-052DCEFAB701Q28367556-D4616CA2-9011-42F2-8329-4F245816BABDQ28367988-C22F8D84-9013-4D77-AD2A-EE3B9A1D8467Q28369082-1DE6CEB6-173B-4D37-ACBB-120BAE627839Q28377216-E7CD6725-9DE5-4182-841E-17E956CEA173Q28378786-57FA47DF-A191-4CAE-B0CA-334C60F28F92Q28378965-F5FF0835-E5DE-40F8-8464-D4F80B2A0762Q28379471-FDBC3B74-14C2-4F25-BF95-50229A626716Q28379530-CB75EBB2-DB1B-4EDB-BA64-7B3DC9EAA055Q29994527-99F68058-95F0-4561-A171-BF9B134CC75FQ31975873-2562252D-240B-4450-85BB-775EF509BE2BQ33697044-C808E572-237E-4AC5-B34E-C5948DBE8ECAQ33749177-C641D055-9729-4F25-912C-5855B4FAA2A9Q33821263-1E1A577B-3329-43C8-82FD-83797D1F41E6Q33906239-6ACD87FE-9FF1-48CB-8BFA-8591160A4DB4Q33981459-81759A91-657A-40C6-AEFD-DDFC27D1B30EQ34058270-90BA7D76-ED82-45E5-BF0F-42E1BD217A68Q34113323-B9114E86-E161-422C-ABBF-6C80E047C71AQ34301688-0483543A-3E66-47C0-98AD-64C351040FD5Q34421999-04814C6B-30CF-44E3-8276-C1294FC84EDAQ34483566-04794287-B6D7-4F2B-8318-458B1B3AD5F1Q34974754-0B172769-7C96-44FF-AB11-26DEC319661BQ35077568-C7BA41EB-D014-4900-8A8A-61148B2FBBFAQ35122784-5235F3B8-1C22-4F71-B2E7-D50D9176832EQ35123273-F458A76B-C959-49BA-82CE-588B0D870BC8Q35742512-C7C47AD4-369E-4939-AA38-241EC49C8FB0Q35854248-7DAF2A20-F57C-4A7D-89C5-EE2730E7A205Q35912640-2DDD932D-BC26-4444-AB2A-E45BABB02433Q36018600-5754FF0F-0229-4867-991A-F67DE09CBB6BQ36951689-E4F99A45-285D-4558-996E-B93A4161B3C6Q37003034-95D15182-6537-4248-A5A5-E5C1B3CA13D0Q37018369-ED900FF2-37EF-42B1-A67E-676551DB2FF1Q37077340-D9AF788D-7D03-45B1-A2BC-5B4397E4D592Q37216862-7F406589-E3E8-4642-8612-56C73BAD5F27Q37333143-54E801B8-B1F5-430B-9968-0864762E7DCEQ37374348-CA6F11D9-B586-40E2-8F76-E0CD4DB7ADC5Q37547347-748D5A8C-0098-4C7E-9CBD-64C9CD70CDB6Q39471742-198BADD1-101C-4C06-B79E-C46B2A3B606EQ39559492-4AAB1A35-C44D-4432-B65E-899A26D75839Q39589219-DE03314B-70D5-4C33-8B3F-1C2DB4B9E9FF
P2860
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.
description
1993 nî lūn-bûn
@nan
1993 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Differential phosphorylation o ...... heral blood mononuclear cells.
@ast
Differential phosphorylation o ...... heral blood mononuclear cells.
@en
type
label
Differential phosphorylation o ...... heral blood mononuclear cells.
@ast
Differential phosphorylation o ...... heral blood mononuclear cells.
@en
prefLabel
Differential phosphorylation o ...... heral blood mononuclear cells.
@ast
Differential phosphorylation o ...... heral blood mononuclear cells.
@en
P2093
P2860
P356
P1476
Differential phosphorylation o ...... heral blood mononuclear cells.
@en
P2093
P2860
P304
P356
10.1172/JCI116463
P407
P577
1993-05-01T00:00:00Z